Trial Profile
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Mar 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Planned primary completion date changed from 1 Apr 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 13 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.